Found 6 results
Filters: Author is Y. Gu  [Clear All Filters]
Y. Gu, Zhou, X., and Zhang, S. L., Meta-analysis of an association of codon 72 polymorphisms of the p53 gene with increased endometrial cancer risk, vol. 10, pp. 3609-3619, 2011.
Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, et al. (2004). P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur. J. Cancer Prev. 13: 277-280. PMid:15554555   Ashton KA, Proietto A, Otton G, Symonds I, et al. (2009). Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol. Oncol. 113: 109-114. PMid:19193430   Berchuck A, Kohler MF, Marks JR, Wiseman R, et al. (1994). The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol. 170: 246-252. PMid:8296829   Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, et al. (1997). Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br. J. Cancer 75: 1385-1388. PMid:9155064 PMCid:2228224   Fan R, Wu MT, Miller D, Wain JC, et al. (2000). The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 9: 1037-1042. PMid:11045785   Ghasemi N, Karimi-Zarchi M, Mortazavi-Zadeh MR and Atash-Afza A (2010). Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer. Cancer Genet. Cytogenet. 196: 167-170. PMid:20082853   Grochola LF, Zeron-Medina J, Meriaux S and Bond GL (2010). Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb. Perspect. Biol. 2: a001032. PMid:20452958 PMCid:2857176   Harris CC and Hollstein M (1993). Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329: 1318- 1327. PMid:8413413   Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. PMid:12111919   Ioannidis JP, Ntzani EE, Trikalinos TA and Contopoulos-Ioannidis DG (2001). Replication validity of genetic association studies. Nat. Genet. 29: 306-309. PMid:11600885   Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300. PMid:20610543   Koushik A, Platt RW and Franco EL (2004). p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol. Biomarkers Prev. 13: 11-22. PMid:14744727   Lax SF (2004). Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 444: 213-223. PMid:14747944   Munafo M (2004). Replication validity of genetic association studies of smoking behavior: what can meta-analytic techniques offer? Nicotine Tob. Res. 6: 381-382. PMid:15203812   Ng TT, McGory ML, Ko CY and Maggard MA (2006). Meta-analysis in surgery: methods and limitations. Arch. Surg. 141: 1125-1130. PMid:17116806   Niwa Y, Hirose K, Matsuo K, Tajima K, et al. (2005). Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett. 219: 183-190. PMid:15723718   Nunobiki O, Ueda M, Yamamoto M, Toji E, et al. (2009). Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum. Cell 22: 101-106. PMid:19874399   Ozalp S, Yalcin OT, Tanir HM, Kabukcuoglu S, et al. (2003). p53 overexpression as a prognostic indicator in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 24: 275-278. PMid:12807239   Pecorelli S, Favalli G, Zigliani L and Odicino F (2003). Cancer in women. Int. J. Gynaecol. Obstet. 82: 369-379.   Peller S, Halperin R, Schneider D, Kopilova Y, et al. (1999). Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol. Rep. 6: 193-197. PMid:9864427   Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. PMid:16467236   Risinger JI, Dent GA, Ignar-Trowbridge D, McLachlan JA, et al. (1992). p53 gene mutations in human endometrial carcinoma. Mol. Carcinog. 5: 250-253. PMid:1497800   Roh JW, Kim JW, Park NH, Song YS, et al. (2004). p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol. 93: 499-505. PMid:15099969   Sherman ME (2000). Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13: 295-308. PMid:10757340   Soliman PT, Oh JC, Schmeler KM, Sun CC, et al. (2005). Risk factors for young premenopausal women with endometrial cancer. Obstet. Gynecol. 105: 575-580. PMid:15738027   Ueda M, Terai Y, Kanda K, Kanemura M, et al. (2006). Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol. Oncol. 100: 173-178. PMid:16168468   Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, et al. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835. PMid:18049195   Viechtbauer W (2007). Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26: 37-52. PMid:16463355   Whibley C, Pharoah PD and Hollstein M (2009). p53 polymorphisms: cancer implications. Nat. Rev. Cancer 9: 95-107. PMid:19165225   Yang HP, Gonzalez BJ, Li Q, Platz EA, et al. (2010). Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis 31: 827-833. PMid:20053928 PMCid:2864407   Ye S (2000). Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol. 19: 623-629.   Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. PMid:15593093   Zubor P, Stanclova A, Kajo K, Hatok J, et al. (2009). The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology 76: 173-183. PMid:19209008   Zucchetto A, Serraino D, Polesel J, Negri E, et al. (2009). Hormone-related factors and gynecological conditions in relation to endometrial cancer risk. Eur. J. Cancer Prev. 18: 316-321. PMid:19554665